Search Results for "PARK2" - 332 interactions found in 68 entries.

Entry-ID
Interactor1 (Subject) Interaction type Interactor2 (Object) additional information
PubMed-ID
Diseases
8
20 LRRK2 interacts (colocalizes) with PARK2
16352719 Parkinson disease
62
1008 PARK2 decreases_activity of neuron death in substantia nigra
15576511 Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
142
510 PARK2 is localized in aggresome if PARK2 is overexpressed
16805805 Parkinson disease
147
531 PARK2 interacts (colocalizes) with PINK1
536 PARK2 NOT interacts (colocalizes) with PINK1-p.H271Q
537 PARK2 NOT interacts (colocalizes) with PINK1-p.G309D
538 PARK2 NOT interacts (colocalizes) with PINK1-p.E417G
539 PARK2 decreases_ubiquitination/sumoylation of PINK1
540 PARK2 NOT decreases_ubiquitination/sumoylation of PINK1-p.H271Q
541 PARK2 NOT decreases_ubiquitination/sumoylation of PINK1-p.G309D
542 PARK2 NOT decreases_ubiquitination/sumoylation of PINK1-p.E417G
9363 PARK2 increases_quantity of PINK1 by inhibiting its ubiquitin-mediated proteasomal degradation
9364 PARK2 NOT increases_quantity of PINK1-p.H271Q by inhibiting its ubiquitin-mediated proteasomal degradation
9365 PARK2 NOT increases_quantity of PINK1-p.G309D by inhibiting its ubiquitin-mediated proteasomal degradation
9366 PARK2 NOT increases_quantity of PINK1-p.E417G by inhibiting its ubiquitin-mediated proteasomal degradation
9367 PARK2 affects_activity of proteasome-mediated ubiquitin-dependent protein catabolic process
19358826 Parkinson disease
148
548 PPD complex increases_ubiquitination/sumoylation of PARK2
558 PINK1 decreases_quantity of PARK2 via ubiquitin-mediated proteasomal degradation
561 PINK1 increases_ubiquitination/sumoylation of PARK2
563 PINK1-p.G309D NOT decreases_quantity of PARK2 via ubiquitin-mediated proteasomal degradation
565 PINK1-p.G309D NOT increases_ubiquitination/sumoylation of PARK2
19229105 Parkinson disease
152
571 PINK1 increases_transport of PARK2 into mitochondria; by phosphorylation of PARK2
4052 PINK1 increases_phosphorylation of PARK2
18957282 Parkinson disease
154
577 PARK2 is localized in mitochondrion in proliferating cells
578 PARK2 is localized in cytoplasm in differentiated or quiescent cells
590 PARK2 interacts (colocalizes) with TFAM in mitochondria
9354 PARK2 increases_activity of TFAM in mitochondria; thus increasing transcription activity in mitochondria
16449237 Parkinson disease
156
2626 PARK2 decreases_activity of neuron death if cell death has been induced by loss of PINK1
2653 PARK2 affects_activity of PINK1
19279012 Parkinson disease
242
1014 MAPT-p.VLW increases_expression of PARK2
19057915 Parkinson disease
403
1731 PARK2 interacts (colocalizes) with microtubule
1734 PARK2 interacts (colocalizes) with TUBB
1736 PARK2 interacts (colocalizes) with TUBA
1737 PARK2 interacts (colocalizes) with Alpha/beta-tubulin complex
1743 PARK2 increases_ubiquitination/sumoylation of TUBB
1744 PARK2 increases_ubiquitination/sumoylation of TUBA
12716939 Parkinson disease
405
1738 PARK2 interacts (colocalizes) with TUBB
1739 PARK2 interacts (colocalizes) with TUBA
1741 PARK2 increases_ubiquitination/sumoylation of TUBB
1742 PARK2 increases_ubiquitination/sumoylation of TUBA
1759 PARK2 decreases_quantity of TUBB via ubiquitin-mediated proteasomal degradation
1760 PARK2 decreases_quantity of TUBA via ubiquitin-mediated proteasomal degradation
12716939 Parkinson disease
466
4007 PARK2 decreases_activity of neuron death
19684592 Parkinson disease
499
2418 PARK2 is localized in cytoplasm
2430 PARK2 is localized in mitochondrion
2431 CCCP increases_transport of PARK2 into mitochondria
2432 mitochondrial depolarization increases_transport of PARK2 into mitochondria
2433 PARK2 increases_activity of mitochondrion degradation
2434 PARK2 interacts (colocalizes) with MAP1LC3A after CCCP treatment
2556 mitochondrial depolarization increases_transport of PARK2 into mitochondria
9829 PARK2 decreases_activity of abnormal mitochondrial physiology by promoting autophagic degradation of mitochondria
19029340 Parkinson disease
500
2460 PARK2 affects_activity of mitochondrial fragmentation involved in apoptotic process which has been induced by PINK1 knockdown
2695 PARK2 affects_activity of PINK1
17989306 Parkinson disease
517
2558 CCCP increases_transport of PARK2 into mitochondria
2559 FCCP increases_transport of PARK2 into mitochondria
2562 PINK1 increases_transport of PARK2 into mitochondria; after CCCP treatment
2563 PARK7 NOT affects transport of PARK2 into mitochondria; after CCCP treatment
2572 PINK1-p.W437X NOT increases_transport of PARK2 into mitochondria
2574 PINK1-p.L347P NOT increases_transport of PARK2 into mitochondria
2579 PARK2 interacts (colocalizes) with PINK1 in mitochondria
2580 PARK2 NOT affects_ubiquitination/sumoylation of PINK1
2582 PARK2 NOT affects_quantity of PINK1 via ubiquitin-mediated proteasomal degradation
2584 PINK1 increases_transport of PARK2 into mitochondria; if PINK1 is overexpressed
9824 PARK2 decreases_activity of abnormal mitochondrial physiology
45616 PARK2 increases_activity of mitochondrion degradation together with Pink1
19966284 Parkinson disease
543
2744 CCCP increases_transport of PARK2 into mitochondria
2785 PARK2 increases_activity of mitochondrion degradation if Parkin is localized in mitochondria
2824 PINK1 affects transport of PARK2 into mitochondria; after CCCP treatment
2850 PARK2 increases_ubiquitination/sumoylation of VDAC1 after CCCP treatment
2857 VDAC1 affects transport of PARK2 into mitochondria; after CCCP treatment
2859 TRAP1 NOT affects transport of PARK2 into mitochondria; after CCCP treatment
20098416 Parkinson disease
558
2899 PARK2 affects_activity of Parkinson disease 2, autosomal recessive juvenile
2900 PARK2 increases_quantity of alpha-synuclein inclusion body
2999 PARK2 is localized in alpha-synuclein inclusion body of the substantia nigra
12000718 Dementia, Lewy body
Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
560
2902 PARK7 NOT interacts (colocalizes) with PARK2
2903 PARK7-p.L166P interacts (colocalizes) with PARK2
2909 PARK2 increases_ubiquitination/sumoylation of PARK7-p.L166P
2911 PARK2 NOT increases_ubiquitination/sumoylation of PARK7
2913 PARK2 NOT decreases_quantity of PARK7-p.L166P via ubiquitin-mediated proteasomal degradation
2915 PARK2 NOT decreases_quantity of PARK7 via ubiquitin-mediated proteasomal degradation
2922 UBE2N interacts (colocalizes) with PARK2
2923 PARK2 interacts (colocalizes) with UBE2G2
2928 PARK2 interacts (colocalizes) with UBE2H
2929 PARK2 NOT interacts (colocalizes) with UBE2D1
2939 PARK2 increases_activity of protein K63-linked ubiquitination of PARK7-L166P , together with UBC13-UEV1a complex
2940 PARK2 increases_ubiquitination/sumoylation of PARK7-p.L166P via K63-linked ubiquitin chains
2942 PARK2 is localized in aggresome after treatment with proteasome inhibitor MG132
2944 PARK2 increases_transport of PARK7-p.L166P into aggresome
2945 PARK2 NOT increases_transport of PARK7 into aggresome
17846173 Parkinson disease
566
2953 PARK2 NOT affects_quantity of PARK7-p.L166P
2954 PARK2 increases_transport of PARK7-p.L166P into aggresome
17846173 Parkinson disease
710
3931 PARK2 interacts (colocalizes) with CTNNB1
3933 PARK2 decreases_quantity of CTNNB1
3950 PARK2 affects_activity of canonical Wnt signaling pathway
3974 PARK2 decreases_quantity of CTNNB1
19591802 Parkinson disease
715
3975 PARK2 decreases_quantity of CTNNB1 in ventral midbrain dopaminergic neurons
3979 PARK2 NOT affects_expression of CTNNB1 in ventral midbrain dopaminergic neurons
3985 PARK2 affects_activity of canonical Wnt signaling pathway in ventral midbrain dopaminergic neurons
3987 PARK2 decreases_quantity of CTNNB1 in ventral midbrain dopaminergic neurons
3988 PARK2 decreases_activity of neuron death in ventral midbrain dopaminergic neurons
19591802 Parkinson disease
720
4058 PARK2 affects_activity of LRRK2
19692353 Parkinson disease
721
4065 PARK2 decreases_activity of neuron death induced by LRRK2-p.G2019S mutant
4066 PARK2 decreases_activity of LRRK2-p.G2019S
19741132 Parkinson disease
785
4397 PARK2 interacts (colocalizes) with LIMK1 also in the presence of CHIP
4398 PARK2 interacts (colocalizes) with LIMK2
4414 PARK2 interacts (colocalizes) with FBXW7
4417 HSP70 interacts (colocalizes) with PARK2
4426 PARK2 increases_ubiquitination/sumoylation of LIMK1 in vitro or in BE(2)-M17 cells, but not in HEK293 cells
4431 PARK2 decreases_activity of LIMK1 in a cell type-dependent manner
4443 PARK2 decreases_activity of actin filament polymerization through ubiquitination of LIMK1
4446 PARK2 increases_activity of actin filament depolymerization through ubiquitination of LIMK1
4455 LIMK1 NOT increases_phosphorylation of PARK2
4456 Protein kinase A increases_phosphorylation of PARK2
4457 PARK2 increases_ubiquitination/sumoylation of PARK2
4459 LIMK1 decreases_activity of PARK2
4462 LIMK1 decreases_ubiquitination/sumoylation of PARK2
17512523 Parkinson disease
823
4757 PARK2 interacts (colocalizes) with UBE2L3
4758 PARK2 interacts (colocalizes) with UBE2L6
4759 PARK2 NOT interacts (colocalizes) with UBE2B
4760 PARK2 NOT interacts (colocalizes) with CDC34
4761 PARK2 NOT interacts (colocalizes) with UBE2D2
4762 PARK2 NOT interacts (colocalizes) with UBE2D1
4763 PARK2 NOT interacts (colocalizes) with UBE2D3
4764 PARK2 NOT interacts (colocalizes) with UBE2E1
4765 PARK2 increases_activity of protein ubiquitination
10888878 Parkinson disease 2, autosomal recessive juvenile
Parkinson disease
825
4774 PARK2 is localized in alpha-synuclein inclusion body in brainstem
4776 PARK2 interacts (colocalizes) with UBE2L3 in brainstem
4779 PARK2 increases_ubiquitination/sumoylation of SNCA
11431533 Parkinson disease
867
5210 GGEL interacts (colocalizes) with PARK2 in UPP (ubiquitin-immunopositive, insoluble protein particles)
15132984 Alzheimer disease
Huntington disease
874
5158 PARK2 NOT interacts (colocalizes) with PSMD5
5160 PARK2 NOT interacts (colocalizes) with Epsin
5161 PARK2 interacts (colocalizes) with EPS15
16862145 Parkinson disease
876
5163 PARK2 interacts (colocalizes) with EPS15
16862145 Parkinson disease
878
5169 PARK2 interacts (colocalizes) with EPS15
5172 PARK2 affects_activity of epidermal growth factor receptor signaling pathway
16862145 Parkinson disease
-->